XOMA Royalty Corporation entered into a merger agreement with Ligand Pharmaceuticals on April 27, 2026, combining the two companies to enhance market position and expand their pharmaceutical portfolio. This strategic transaction represents a significant corporate event with material implications for shareholders, though specific financial terms have not yet been disclosed.

On April 27, 2026, XOMA Royalty Corporation entered into a Merger Agreement with Ligand Pharmaceuticals Incorporated and Flex, which outlines the terms for the merger of the companies. This agreement represents a significant strategic move for XOMA as it partners with Ligand, a notable player in the pharmaceuticals sector. The details of the merger reveal plans for collaboration that could enhance their combined market capabilities. The transaction's impact on shareholders and the potential financial terms of the merger are expected to be significant, although specific financial amounts have not been disclosed in this summary.

Real-time funding, M&A, exec moves & hiring — the signals that move deals

XOMA Royalty Corporation

AI Executive Summary

Key Takeaways

Raw Filing Content

Filing Overview

What This Means